(Q50578983)

English

Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.

scientific article published in June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

Ulrike Ravens-Sieberer

5

object named as

Ulrike Ravens-Sieberer

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

Monika Bullinger

8

object named as

Monika Bullinger

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

Bärbel-Maria Kurth

7

object named as

Bärbel M Kurth

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

author name string

Uwe Siebert

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

Gaby Sroczynski

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

Wolfgang Greiner

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

Pamela Aidelsburger

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

J-Matthias Graf von der Schulenburg

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

John B Wong

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

Siegbert Rossol

11

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

The European Journal of Health Economics

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

112-123

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

https://scigraph.springernature.com/pub.10.1007/s10198-005-0280-7

0 references

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

45-year follow-up of hepatitis C virus infection in healthy young adults

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

High-priced technology can be good value for money.

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989.

1 reference

https://api.crossref.org/works/10.1007%2FS10198-005-0280-7

21 January 2018

Identifiers

10.1007/S10198-005-0280-7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/15902546

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50578983&oldid=1540642900"